TY - JOUR
T1 - Statin use and all-cause and cancer mortality
T2 - BioBank Japan cohort
AU - BioBank Japan Cooperative Hospital Group
AU - Yokomichi, Hiroshi
AU - Nagai, Akiko
AU - Hirata, Makoto
AU - Tamakoshi, Akiko
AU - Kiyohara, Yutaka
AU - Kamatani, Yoichiro
AU - Muto, Kaori
AU - Ninomiya, Toshiharu
AU - Matsuda, Koichi
AU - Kubo, Michiaki
AU - Nakamura, Yusuke
AU - Yamagata, Zentaro
AU - Misumi, Kazuo
AU - Higa, Nobuyoshi
AU - Matsubayashi, Sunao
AU - Matsuura, Kei
AU - Minami, Shiro
AU - Sugihara, Hitoshi
AU - Emoto, Naoya
AU - Ohmura, Hirotoshi
AU - Inui, Akihiro
AU - Ogasawara, Michihiro
AU - Asai, Satoshi
AU - Moriyama, Mitsuhiko
AU - Takahashi, Yasuo
AU - Fujioka, Tomoaki
AU - Obara, Wataru
AU - Mori, Seijiro
AU - Ito, Hideki
AU - Nagayama, Satoshi
AU - Miki, Yoshio
AU - Masumoto, Akihide
AU - Yamada, Akira
AU - Nishizawa, Yasuko
AU - Kodama, Ken
AU - Ugi, Satoshi
AU - Maegawa, Hiroshi
AU - Koretsune, Yukihiro
AU - Kusuoka, Hideo
AU - Ueyama, Masako
N1 - Funding Information:
This work was supported by funding from the Tailor-Made Medical Treatment Program with the BioBank Japan Project from Japan Agency for Medical Research and development (AMED) since April 2015 and the Ministry of Education,Culture,Sports,Science,and Technology (MEXT) from April 2003 to March 2015. This work was also supported by MEXT [KAKENHI grant number: JP15K08730 and JP15K15221].
PY - 2017
Y1 - 2017
N2 - Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. KaplaneMeier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64e66 years and mean body mass indices of 24e25 kg/m2. Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statinmonotherapycouldpotentially reduceany-organ- andcolorectal cancer-relatedmortality.
AB - Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. KaplaneMeier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64e66 years and mean body mass indices of 24e25 kg/m2. Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statinmonotherapycouldpotentially reduceany-organ- andcolorectal cancer-relatedmortality.
UR - http://www.scopus.com/inward/record.url?scp=85016403176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016403176&partnerID=8YFLogxK
U2 - 10.1016/j.je.2016.12.011
DO - 10.1016/j.je.2016.12.011
M3 - Article
C2 - 28196737
AN - SCOPUS:85016403176
VL - 27
SP - S84-S91
JO - Journal of Epidemiology
JF - Journal of Epidemiology
SN - 0917-5040
IS - 3
ER -